Top

Published in:

01-02-2016 | DIAGNOSTIC IMAGING IN ONCOLOGY

Role of WB-MR/DWIBS compared to ¹⁸F-FDG PET/CT in the therapy response assessment of lymphoma

Authors: Nicola Maggialetti, Cristina Ferrari, Carla Minoia, Artor Niccoli Asabella, Michele Ficco, Giacomo Loseto, Giacomina De Tullio, Vincenza de Fazio, Angela Calabrese, Attilio Guarini, Giuseppe Rubini, Luca Brunese

Published in: La radiologia medica | Issue 2/2016

Abstract

Introduction

This study prospectively evaluated whole-body magnetic resonance/diffusion-weighted imaging with body signal suppression (WB-MR/DWIBS) reliability compared to ¹⁸F-FDG PET/CT in the treatment response assessment of classic Hodgkin lymphomas (HL) and aggressive non-Hodgkin lymphomas (aNHL).

Materials and methods

Twenty-seven consecutive patients were prospectively enrolled at the time of diagnosis. Eighteen (11 HL and seven aNHL) were considered for the analysis. They received chemo/radiotherapy as induction and completed post-treatment evaluation performing both ¹⁸F-FDG PET/CT and WB-MR/DWIBS. The revised response criteria for malignant lymphomas were used to assess the response to treatment. We evaluated the agreement between the two methods by Cohen’s K test. Post-therapy WB-MR/DWIBS sensitivity, specificity, PPV, NPV and accuracy were then calculated, considering the 12 months of follow-up period as the gold standard.

Results

By using an evaluation on a lesion-by-lesion basis, WB-MR/DWIBS and ¹⁸F-FDG PET/CT showed an overall good agreement (K = 0.796, 95 % IC = 0.651–0.941), especially in the evaluation of the nodal basins in aNHL (K = 0.937, 95 % IC = 0.814–1). In reference to the revised response criteria for malignant lymphomas, the two methods showed a good agreement (K = 0.824, 95 % IC = 0.493–1). Post-therapy sensitivity, specificity, PPV, NPV and accuracy of WB-MR/DWIBS were 43, 91, 75, 71 and 72 %, respectively.

Conclusion

WB-MR/DWIBS seems to be an appropriate method for the post-treatment assessment of patients affected by HL and aNHL. The small discrepancies between the two methods found within HL could be due to the biological and metabolic behavior of this group of diseases. Larger prospective studies are necessary to better define the role of WB-MR/DWIBS in this setting of patients.

Wu X, Kellokumpu-Lehtinen PL, Pertovaara H, Korkola P, Soimakallio S, Eskola H et al (2011) Diffusion-weighted MRI in early chemotherapy response evaluation of patients with diffuse large B-cell lymphoma–a pilot study: comparison with 2-deoxy-2-fluoro- d-glucose-positron emission tomography/computed tomography. NMR Biomed 24(10):1181–1190PubMedCrossRef

Antoch G, Vogt FM, Freudenberg LS, Nazaradeh F, Goehde SC, Barkhausen J et al (2003) Wholebody dual-modality PET/CT and whole-body MRI for tumor staging in oncology. J Am Med Assoc 290:3199–3206CrossRef

Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17(4):1244PubMed

Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579–586PubMedCrossRef

Wu X, Pertovaara H, Korkola P, Dastidar P, Järvenpää R, Eskola H et al (2014) Correlations between functional imaging markers derived from PET/CT and diffusion-weighted MRI in diffuse large B-Cell lymphoma and follicular lymphoma. PLoS One 9(1):e84999PubMedPubMedCentralCrossRef

Zink D, Fischer AH, Nickerson JA (2004) Nuclear structure in cancer cells. Nat Rev Cancer 4:677–687PubMedCrossRef

Takahara T, Imai Y, Yamashita T et al (2004) Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med 22(4):275–282PubMed

Brennan DD, Gleeson T, Coate LE et al (2005) A comparison of whole-body MRI and CT for the staging of lymphoma. AJR Am J Roentgenol 185(3):711–716PubMedCrossRef

Kwee TC, Kwee RM, Nievelstein RA (2008) Imaging in staging of malignant lymphoma: a systematic review. Blood 111(2):504–516PubMedCrossRef

10.

Punwani S, Taylor SA, Saad ZZ, Bainbridge A, Groves A, Daw S et al (2013) Diffusion-weighted MRI of lymphoma: prognostic utility and implications for PET/MRI? Eur J Nucl Med Mol Imaging 40(3):373–385PubMedCrossRef

11.

Marzolini M, Wong WL, Ardeshna K, Padhani A, D’Sa S (2012) Diffusion-weighted MRI compared to FDG PET-CT in the staging and response assessment of Hodgkin lymphoma. Br J Haematol 156(5):557PubMedCrossRef

12.

Chen Y, Zhong J, Wu H, Chen N (2012) The clinical application of whole-body diffusion-weighted imaging in the early assessment of chemotherapeutic effects in lymphoma: the initial experience. Magn Reson Imaging 30(2):165–170PubMedCrossRef

13.

Lin C, Luciani A, Itti E et al (2010) Whole-body diffusion-weighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large B-cell lymphoma. Eur Radiol 20(8):2027–2038PubMedCrossRef

14.

Ferrari C, Minoia C, Asabella AN, Nicoletti A, Altini C, Antonica F, Ficco M et al (2014) Whole body magnetic resonance with diffusion weighted sequence with body signal suppression compared to (18)F-FDG PET/CT in newly diagnosed lymphoma. Hell J Nucl Med 17Suppl(1):40–49

15.

Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A et al (2007) Imaging Subcommittee of International Harmonization Project in Lymphoma. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25(5):571–578PubMedCrossRef

16.

De Paepe K, Bevernage C, De Keyzer F, Wolter P, Gheysens O, Janssens A et al (2013) Whole-body diffusion-weighted magnetic resonance imaging at 3 Tesla for early assessment of treatment response in non-Hodgkin lymphoma: a pilot study. Cancer Imaging 13:53–62PubMedPubMedCentralCrossRef

17.

Kostakoglu L, Cheson BD (2013) State-of-the-art research on lymphomas: role of molecular imaging for staging, prognostic evaluation, and treatment response. Front Oncol 3:212PubMedPubMedCentralCrossRef

18.

Komori T, Narabayashi I, Matsumura K et al (2007) 2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: initial experience. J Ann Nucl Med 21:209–215CrossRef

19.

Nakanishi K, Kobayashi M, Nakaguchi K et al (2007) Whole-body MRI for detecting metastatic bone tumor: diagnostic value of diffusion weighted images. J Megn Reson Med Sci 6(3):147–155CrossRef

20.

Ohno Y, Koyama H, Onishi Y et al (2008) Non-small cell lung cancer: whole-body MR examination for M-stage assessment—utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. J Radiol 248:643–654CrossRef

21.

Cui Y, Zhang XP, Sun YS et al (2008) Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. J Radiol 248(3):894–900CrossRef

22.

Barajas RF Jr, Rubenstein JL, Chang JS, Hwang J, Cha S (2010) Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma. AJNR Am J Neuroradiol 31(1):60–66PubMedPubMedCentralCrossRef

23.

Gu J, Chan T, Zhang J, Leung AY, Kwong YL, Khong PL (2011) Whole body diffusion-weighted imaging: the added value to whole-body MRI at initial diagnosis of lymphoma. AJR Am J Roentgenol 197(3):W384–W391PubMedCrossRef

24.

Abdulqadhr G, Molin D, Aström G et al (2011) Whole-body diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patients. Acta Radiol 52(2):173–180PubMedCrossRef

25.

vanUfford HM, Kwee TC, Beek FJ et al (2011) Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT (2011). AJR Am J Roentgenol 196(3):662–669CrossRef

26.

Stéphane V, Samuel B, Vincent D, Joelle G, Remy P, Francois GG et al (2013) Comparison of PET-CT and magnetic resonance diffusion weighted imaging with body suppression (DWIBS) for initial staging of malignant lymphomas. Eur J Radiol 82(11):2011–2017PubMedCrossRef

27.

Ciliberto M, Maggi F, Treglia G, Padovano F, Calandriello L, Giordano A et al (2013) Comparison between whole-body MRI and Fluorine-18-Fluorodeoxyglucose PET or PET/CT in oncology: a systematic review. Radiol Oncol 47(3):206–218PubMedPubMedCentralCrossRef

28.

Kwee TC, Takahara T, Ochiai R et al (2010) Complementary roles of whole-body diffusion-weighted MRI and 18F-FDG PET: the state of the art and potential applications. J Nucl Med 51(10):1549–1558PubMedCrossRef

29.

Saboo SS, Krajewski KM, O’Regan KN et al (1009) Spleen in haematological malignancies: spectrum of imaging findings. Br J Radiol 2012(85):81–92

30.

Eberle FC, Mani H, Jaffe ES (2009) Histopathology of Hodgkin’s lymphoma. Cancer J 15(2):129–137PubMedCrossRef

Title: Role of WB-MR/DWIBS compared to 18F-FDG PET/CT in the therapy response assessment of lymphoma
Authors: Nicola Maggialetti
Cristina Ferrari
Carla Minoia
Artor Niccoli Asabella
Michele Ficco
Giacomo Loseto
Giacomina De Tullio
Vincenza de Fazio
Angela Calabrese
Attilio Guarini
Giuseppe Rubini
Luca Brunese
Publication date: 01-02-2016
Publisher: Springer Milan
Published in: La radiologia medica / Issue 2/2016
Print ISSN: 0033-8362
Electronic ISSN: 1826-6983
DOI: https://doi.org/10.1007/s11547-015-0581-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Role of WB-MR/DWIBS compared to ¹⁸F-FDG PET/CT in the therapy response assessment of lymphoma

Abstract

Introduction

Materials and methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2016

Cumulative doses analysis in young trauma patients: a single-centre experience

Comparison study of reconstruction algorithms for prototype digital breast tomosynthesis using various breast phantoms

Effectiveness of Magnetic Resonance-guided Focused Ultrasound Surgery (MRgFUS) in the uterine adenomyosis treatment: technical approach and MRI evaluation

Irreversible electroporation of hepatocellular carcinoma: preliminary report on the diagnostic accuracy of magnetic resonance, computer tomography, and contrast-enhanced ultrasound in evaluation of the ablated area

Patient dose evaluation for the whole-body low-dose multidetector CT (WBLDMDCT) skeleton study in multiple myeloma (MM)

The role of contrast enhanced computed tomography in the diagnosis of necrotizing fasciitis and comparison with the laboratory risk indicator for necrotizing fasciitis (LRINEC)